AFP and hepatocellular carcinoma: In our study, the diagnostic performance of PIVKA‐II in patients who did not express high serum AFP levels was moderate in the whole group (AUROC 78.5%) as well as among BCLC‐0/A (AUROC 62.4%) and BCLC‐B (AUROC 76.7%) patients and was very good among HCC patients of advanced BCLC‐C stage (AUROC 88.5%).